INNOVATION IN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION: STIMULATOR OF SOLUBLE GYANYLATE CYCLASE - RIOCIGUAT

Pulmonary arterial hypertension (PAH) is a rare disease, diagnosed at a late stage with low functional class III or IV (WHO). PAH leads to severe right heart failure and ultimately, death. The modern researches aim at exploring the potential therapeutic targets, as at developing new drugs that can affect the previously set target. Impaired NO production plays an important role in PAH pathogenesis; this is determined by the powerful vasodilatory action, as well as anti-inflammatory, anti-proliferative, and antiaggregatory effects. Riociguat is the first in a new class of soluble guanylatecyclase stimulators to have proved efficacy in phase II of clinical trials. In the randomized, double-blind, placebo-controlled phase III study PATENT-1 (Pulmonary Arterial Hypertension soluble Guanilatcyclase-Stimulator Trial) study, 443 patients with PAH symptoms were randomized to receive placebo of riociguat in a single dose of 2,5 mg (with a dose titration based on tolerability to 2,5 mg TID a day) or a dose of 1,5 mg (with a dose titration according to portability to 1,5 mg TID three times a day). The study included naïve patients treated with endothelin receptor antagonists or prostanoids (except for parenteral ones). To 12wk of riociguat treatment the mean distance in 6-MWT increased by an average of 30 m in the group treated with the maximum single dose of 2,5 mg TID, or decreased by an average of 6m in the placebo group (difference between groups, 36 m, 95% confidence interval 20-52 m, p p<0,001). Riociguat improved 6-MWT in patients not previously treated with PAH-specific therapy (38 m), and in patients, taking endothelin receptor antagonists or prostanoids (36 m). In riociguat groups compared with placebo a decrease in PVR and PAPm (p<0,01) was noted, as well as an increase in cardiac index (p<0,0001) , a reduction in NT-proBNP (p<0,0001) , FC (p=0,003) and in the Borg index (p=0,002), ), the time of development of clinical deterioration (p=0,005) prolonged as well. Riociguat therapy was also characterized by good tolerance. Efficacy of treatment was maintained during long-term observation of PATENT-2study. The mean value of 6-MWT changed to 51±74 м

1. Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society., endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J 2009; 30 (20): 2493-537.

2. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic., familial., and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122:156-63.

3. Чазова И.Е., Авдеев С.Н., Царева Н.А., Мартынюк Т.В., Волков А.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению лёгочной гипертензии. Терапевтический архив. 2014;9:4-23

4. Chockalingam A., Gnanavelu G., Venkatesan S., Elangovan S., Jagannathan V., Subramaniam T., Alagesan R., Dorairajan S. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005;99:91-95.

5. Leuchte H.H., Schwaiblmair M., Baumgartner R.A., Neurohr C.F., Kolbe T., Behr J. Hemodynamic response to sildenafil., nitric oxide., and iloprost in primary pulmonary hypertension. Chest. 2004;125:580-586.

6. Schermuly R.T., Stasch J.P., Pullamsetti S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32:881-91.

7. Grimminger F., Weimann G., Frey R. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33:785-92.

8. Mittendorf J., Weigand S., Alonso-Alija C et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009; 4:853-65.

9. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-21.

10. Joachim Mittendorf Prof. Dr.1., Stefan Weigand Dr.1,4, Cristina Alonso-Alija Dr.1 Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension ChemMedChem Volume 4., Issue 5, pages 853-865., May 11.,2009

11. Evgenov O., Ichinose F., Evgenov N., Gnoth M., Falkowski G., et al. (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110:2253-2259

12. Dumitrascu R., Weissmann N., Ghofrani H., Dony E., Beuerlein K., et al. (2006) Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113:286-290

13. Ghofrani H., Voswinckel R., Gall H. et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6:155-66.

14. Ghofrani H.A., Galiè N., Grimminger F. et al. Riociguat for the Treatment of рulmonary Arterial Hypertension. N Engl J Med 2013; 369:330-40.

15. Lewis J. Rubin., Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie, Hossein-Ardeschir Ghofrani. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May;45(5):1303-13.

16. Calculation of REVEAL risk scores for patients with PAH receiving riociguat in the PATENT -2 study. Raymond L Benza., Adaani Frost,Harrison Farber, Hossein

17. Adempas (riociguat) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2013 Oct

18. Marius M. Hoeper, Raymond L. Benza, Gerald Simonneau et al. Design and rationale of the RESPITE study: riociguat in patients with pulmonary arterial hypertension and an inadequate responsw to phosphodiesrerase type 5 inhibitors.